Physician profile
Judy Wang
NPI 1053554717
$64,473.24
in general payments reported to CMS, 2019-2025
88 companies · $864 in 2025
The $864 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $2,377 · 2021: $30K · 2022: $8,827 · 2023: $384 · 2024: $568 · 2025: $864.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,816.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,816.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $46,275.59 | 2019-2025 | Imfinzi |
| Eisai INC. | $7,754.56 | 2020-2022 | |
| Stemline Therapeutics INC. | $3,360.00 | 2021 | |
| Merck Sharp & Dohme LLC | $759.12 | 2019-2025 | Keytruda, Lynparza |
| Lilly USA, LLC | $530.55 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $455.57 | 2019-2024 | Opdivo, Opdualag |
| Daiichi Sankyo INC. | $367.39 | 2020-2025 | Enhertu, Datroway |
| Seagen INC. | $333.31 | 2020-2023 | Padcev, Tukysa |
| Janssen Biotech, INC. | $316.61 | 2019-2023 | Imbruvica, Talvey, Tecvayli |
| Incyte Corporation | $301.96 | 2020-2023 | Jakafi |
| Celgene Corporation | $282.54 | 2019-2022 | |
| Array Biopharma INC | $254.03 | 2020-2025 | Braftovi, Lorbrena, Mektovi |
| Pfizer INC. | $227.07 | 2019-2025 | |
| Abbvie INC. | $225.39 | 2022-2025 | |
| Genzyme Corporation | $177.80 | 2020-2022 |
Show all 68 companies
20 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Judy Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.